Full-Time
Develops therapeutics targeting aging mechanisms
$130k - $160k/yr
Mid, Senior
San Carlos, CA, USA
In Person
Retro Biosciences focuses on extending healthy human lifespan by ten years through the development of therapeutics that target the cellular mechanisms of aging. The company addresses the root causes of age-related diseases, which are responsible for a significant portion of healthcare costs in the U.S. Retro Biosciences operates three main programs: cellular reprogramming, plasma-inspired therapeutics, and autophagy, each at different stages of development. They utilize advanced technologies like single-cell multi-omics and computational biology to support their research. Unlike many competitors, Retro Biosciences aims to prevent multiple diseases rather than just treating them, positioning itself uniquely in the biotech field. The company's goal is to reduce healthcare costs associated with aging and improve overall health outcomes by successfully developing and commercializing its therapeutic candidates.
Company Size
51-200
Company Stage
Early VC
Total Funding
$180M
Headquarters
Redwood City, California
Founded
2021
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Paid Holidays
Parental Leave
Professional Development Budget
MCRI, a flagship member of the Melbourne Biomedical Precinct and the Melbourne arm of the international research consortium, the Novo Nordisk Foundation Center for Stem Cell Medicine, reNEW, has today announced a significant research and commercial licensing agreement with Retro Biosciences.
By integrating MCRI's cutting-edge discoveries with its proprietary platforms, Retro Biosciences aims to develop novel, autologous blood stem cell therapies that could eliminate the fatal risks associated with donor mismatches and immunological rejection.
Retro Biosciences, a longevity startup, has partnered with the Murdoch Children’s Research Institute in Australia to develop personalized blood disorder therapies. The company, backed by Sam Altman, is seeking $1 billion in funding.
Sam Altman is backing Retro Biosciences with a new funding round of $1 billion to extend human lifespan.
Retro Biosciences, a biotech company backed by OpenAI CEO Sam Altman, plans to raise $1 billion to fund its project aimed at extending human lifespan by 10 years. Altman initially provided $180 million in seed funding and will contribute more in the Series A round.